Gastroesophageal reflux disease (GERD) is arguably the most common chronic gastrointestinal disorder, characterized by symptoms of heartburn and regurgitation. The primary objectives of GERD treatment are to provide symptom relief, heal erosive esophagitis, and prevent future complications. Available treatment options for GERD are limited; over-the-counter (OTC) antacids are frequently used for acute symptom relief, while proton pump inhibitors (PPIs) have remained the mainstay of chronic therapy, along with lifestyle modifications. However, there is growing concern regarding the side effects associated with long-term use of PPIs, and the number of patients who are nonresponsive to PPIs is increasing, leading to possible shifts in the treatment approach. This report provides insights into current patient-level drug-prescribing patterns among newly diagnosed and recently treated GERD patients.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed GERD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed GERD patients?
  • How have PPIs and histamine H2-receptor antagonists been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of GERD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of GERD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?



United States

Real-world data

Longitudinal patient-level claims data analysis

Key drugs covered

Proton pump inhibitors, histamine H2-receptor antagonists, antacids, and gastroprokinetic agents

Key analysis provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Gastroesophageal Reflux Disease - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis: GERD (US) April 2019

Author(s): Matthew W. Scutcher, MEng PhD; Ritesh Gupta, PhD

Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.  

In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry

He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.

Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease.

He holds a Ph.D. degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.